 certain subgroups of patients who
have demonstrated inferior outcomes, particularly younger
patients (age <50 years), hypercoagulable patients, and those
with very small-caliber outﬂow vessels.180 Younger patients
with premature AIOD are a high-risk group reﬂecting poorly
controlled risk factors, underlying genetic or biochemical predispositions, and a more aggressive vascular phenotype.183
Conservative management of younger patients with AIOD
is advocated because